Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SML2460

Sigma-Aldrich

SK33

≥98% (HPLC)

Sinonimo/i:

3-[3,5-Bis(trifluoromethyl)phenoxy]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C20H13F9N2O3
Numero CAS:
Peso molecolare:
500.31
Codice UNSPSC:
12352200
NACRES:
NA.77

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

2-8°C

Stringa SMILE

OC(C(NC1=CC(C(F)(F)F)=C(C#N)C=C1)=O)(C)COC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2

InChI

1S/C20H13F9N2O3/c1-17(33,16(32)31-13-3-2-10(8-30)15(7-13)20(27,28)29)9-34-14-5-11(18(21,22)23)4-12(6-14)19(24,25)26/h2-7,33H,9H2,1H3,(H,31,32)
VJIVKRQGSGBLFP-UHFFFAOYSA-N

Azioni biochim/fisiol

SK33, a trifluoromethylated enobosarm analog, is a cell and brain penetrant, tissue selective and highly potent anti-androgen that reduces androgen receptor (AR) transcriptional activity. SK33 induces cell cycle arrest at G1 phase. It exhibits increased efficacy against acquired anti-androgen resistance prostate cancer cells.
cell and brain penetrant, tissue selective and highly potent anti-androgen that reduces androgen receptor (AR) transcriptional activity

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Salvatore Ferla et al.
Bioorganic & medicinal chemistry letters, 26(15), 3636-3640 (2016-06-16)
Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of
D Alwyn Dart et al.
Molecular cancer therapeutics, 17(9), 1846-1858 (2018-06-14)
Prostate cancer often develops antiandrogen resistance, possibly via androgen receptor (AR) mutations, which change antagonists to agonists. Novel therapies with increased anticancer activity, while overcoming current drug resistance are urgently needed. Enobosarm has anabolic effects on muscle and bone while

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.